Albiglutide

阿必鲁肽

Report date: 2022/01/19 20:00:34

Base Information

Drug NameAlbiglutide
Drug Alias Name阿必鲁泰Albumin/glucagon-like peptide-1 fusion proteinAlbumin-glucagon-like peptide-1 fusion protein阿比鲁泰Glucagon-like peptide-1-albumin fusion protein +[19] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[4] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2014/03/20
Country/TerritoryUnited StatesTaiwanPhilippines +[24] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Trading Services LtdGlaxosmithkline PlcGlaxosmithkline Llc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[4] 

Other Information

ATC CodeA10BJ04
Related LinksWikipediaDrugBankKEGG